Pulmonary Arterial Hypertension Market - 4.95% CAGR to 2021
PUNE, India, August 17, 2016 /PRNewswire/ --
The Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) report says that PAH market is set to grow at a moderate rate; ERA to the drive the Pulmonary Arterial Hypertension market and the market to be dominated by North America and Europe.
Complete report on Pulmonary Arterial Hypertension (PAH) Market spreads across 140 pages, provides 12 tables and 34 figures is now available at http://www.reportsnreports.com/reports/657034-global-pulmonary-arterial-hypertension-pah-market-by-drug-class-by-region-by-country-opportunities-and-forecasts-2016-2021-by-drug-class-endothelin-receptor-antagonists-prostacyclin-prostacyclin-analogs-phosphodiesterase-v-inhibitors-others-by-region-north-america-europe-apac-latin-america-mea-by-country-usa-canada-uk-germany-japan-brazil-south-africa-.html.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).
The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 - 2021F, on account of rising prevalence of the PAH disease among the population.
North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.
Order a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=657034
According to research report, Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa).
Company Profiled are Actelion Pharmaceuticals Ltd., United Therapeutics Corporation, Gilead sciences, Bayer AG, SteadyMed Ltd., GlaxoSmithKline plc, Pfizer Inc., Reata Pharmaceuticals Inc., Arena Pharmaceuticals Inc. and Merck & Co. Inc.
Other related report is Global Chronic Obstructive Pulmonary Disease Drugs Market 2016 - 2020. Analysts forecast global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.
According to the report, increase in smoking prevalence will be the key driver for market growth. Tobacco smoking is considered to be the leading cause of COPD, with 85% of the cases being because of this reason. The other 15% may be due to the exposure to second-hand smoke, air pollution, chest infections, and genetic disorders such as AAT deficiency. Thus, the rising smoking population is expected to increase the number of individuals with COPD, which increases the treatment-seeking population and drives the market.
The following companies are the key players in the global chronic obstructive pulmonary disease (COPD) drugs market: AstraZeneca, Boehringer Ingelheim, Merck, and Novartis. Read more at http://www.reportsnreports.com/reports/641549-global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020.html.
Explore other reports on Pharmaceuticals Market http://www.reportsnreports.com/market-research/pharmaceuticals/.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. + 1 888 391 5441 email@example.com
Connect With Us on: Facebook: https://www.facebook.com/ReportsnReports/ LinkedIn: https://www.linkedin.com/company/reportsnreports Twitter: https: //twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml